

CPH Chemie + Papier Holding AG

Switzerland | Industrial Goods & Services

Company update


18 October 2016

Company Data

Price:	CHF 40.00
Market Cap:	CHF 240.0mn
Free Float:	41.7%
No. of shares:	6.0mn
Avg. traded volume (1 year):	919
Bloomberg:	CPHN SW
Reuters:	CPHN-EB
ISIN:	CH0001624717

Source: SIX Swiss Exchange and Bloomberg

Share Price Development



Source: Bloomberg

Key Financial Data

	2014	2015	2016E	2017E
Sales	492.5	420.0	458	493
EBITDA %	10.3	2.9	10.1	11.0
EBIT %	3.3	-5.2	2.6	3.7
Net Margin %	2.1	-7.9	0.3	2.3
Basic EPS	1.8	-5.5	0.2	1.9
Diluted EPS	1.8	-5.5	0.2	1.9
DPS	0.65	0.0	-	0.8
Equity Ratio %	64.2	64.5	62.0	62.3
Capex	19.4	22.0	51.2	24.1
P/E	22.9x	NM	156.1x	18.5x
EV/EBITDA	6.2x	25.8x	6.2x	5.3x

Next Events

Annual Results Conference & Investor Meeting	24 February 2017
Annual General Meeting	21 March 2017

Analysts

Doris Rudischauser
dru@researchdynamics.ch

Alexandre Müller
amu@researchdynamics.ch

Tel: +41 43 268 3232

www.researchdynamics.ch

Site for new European manufacturing unit acquired

CPH Chemie + Paper Holding AG (CPH/the group) is a diversified industrial group with presence in paper, chemical products and pharma packaging films industries. CPH generates around 60% of its revenues from the Paper division, where almost all sales come from Europe. CPH is one of only two newsprint paper producers in the Swiss market and the country's sole magazine paper producer. The Packaging division manufactures high barrier films for the global pharmaceutical industry and is the third-largest supplier of PVdC coated high-barrier films. The Chemistry division produces molecular sieves and has a global exposure. In 1H2016, CPH's net sales stood at CHF 219.5mn, up 10% y/y, and – following the completion of the acquisition of China-based ALSIO – had an employee headcount of 1,001.

Land acquisition to diversify manufacturing base

CPH Chemie + Paper Holding AG announced today that it has purchased a 5,400 meter square industrial site in Bosnia and Herzegovina. The company's chemicals' subsidiary, Zeochem, intends to build a plant to manufacture molecular sieve powders (Purmol), specialty zeolites (ZEOflair) and silica chromatography gels (ZEOprep) at the newly acquired land in Zvornik. The new plant is expected to be completed by end of 2017 with "high-single-digit million-franc" investment and to employ 40 personnel. The acquisition of an industrial land in Europe will extend the production sites of the Chemistry division from two (one in Louisville/USA and one in Lianyungang/China) to three, thus re-balancing the global presence of the Group once the relocation of the Uetikon site will be concluded. The new site is also in proximity to Alumina d.o.o., a long term partner of Zeochem for its downstream materials supply, which would lower transportation costs for the company.

Sale of Uetikon facility

Uetikon was the place the company's Chemistry division was founded in 1818. The sale of the site was finalized earlier this year after lengthy negotiations, with the Canton of Zurich agreeing to purchase the 65,000 square metres of industrial land from the CPH group. The total sales price of CHF 52 mn includes CHF 32 mn for environmental clean-up of the site, which will be held back by the Canton. The two-year lease back period between the two parties gives CPH time to continue with its current activities (R&D, production and administration) on the site till the relocation is completed. The rationale behind the sale was primarily to make the Chemistry division more competitive on a global basis by reducing the Swiss cost base.

In line with the Chemistry segment's strategy

Transferring its production over a two-year period from Switzerland to a) China – by way of acquiring 80% of molecular sieve manufacturer ALSIO – and b) building a European plant in Bosnia and Herzegovina is thus a consequent step in the division's strategy. By increasing production capacities in lower cost regions, the division intends to reduce the cost of production and help improve margins in the current tough economic environment. In addition, it will also reduce the company's exposure to the Swiss Franc as well as increase the share of revenues from outside of Europe, which is the Group's strategic objective. While with this investment CAPEX is expected to increase this year and next, we are leaving our estimates unchanged at this stage, as the division's outlook for this year and next remains unchanged (expected increase in sales and improved margins).

Valuation and conclusion

The CPH stock has outperformed the Swiss market over the last few months. Given its low profitability during the current transformation/restructuring phase, we look at the company's sales and EBITDA multiples. CPH currently trades at a 45% discount to the 2016 peer average P/S, and a 47% discount to the 2017 P/S. Looking at the EV/EBITDA multiple, the company trades at a 8% discount to its peers on 2016 estimates and 25% discount to peers on 2017 forecast.

With operating profit expected to grow at a CAGR of more than 30% between 2016E and 2019E, we think the stock could command a higher multiple.

Exhibit 1: CPH – Comparison with division peers

Company	EV/EBITDA			P/S			P/E		
	3 year average	CY2016E	CY2017E	3 year average	CY2016E	CY2017E	3 year average	CY2016E	CY2017E
CPH Chemie & Paper	13.7x	6.8x	5.8x	0.5x	0.5x	0.5x	26.8x	175.3x	20.7x
Paper peers:									
Holmen	11.4x	10.4x	10.0x	1.3x	1.6x	1.7x	27.6x	16.7x	16.2x
Stora Enso	8.0x	6.9x	6.9x	0.6x	0.7x	0.7x	36.0x	12.2x	10.8x
Altri	8.4x	7.0x	7.8x	1.0x	1.1x	1.1x	10.8x	8.9x	10.8x
Metsa Board	9.3x	9.1x	7.1x	0.8x	1.1x	1.0x	19.3x	17.9x	11.9x
UPM-Kymmene	6.4x	6.6x	6.7x	0.7x	1.0x	1.0x	14.8x	12.7x	13.1x
Norskse Scogindustrier	NA	6.1x	8.6x	NA	0.1x	0.1x	NA	-3.1x	-1.1x
James Cropper	9.9x	NA	NA	0.6x	0.0x	0.0x	24.9x	25.3x	20.9x
OJI Holdings	NA	NA	NA	NA	0.3x	0.3x	NA	35.1x	9.9x
Chemistry peers:									
Honeywell Int.	11.8x	11.0x	10.3x	2.0x	2.1x	2.0x	17.3x	16.5x	15.3x
Clariant	10.4x	8.1x	7.8x	0.9x	0.9x	0.9x	24.5x	14.7x	13.2x
Arkema	7.0x	6.7x	6.2x	0.7x	0.8x	0.8x	21.7x	15.9x	13.9x
WR Grace & Co.	15.3x	12.5x	11.4x	1.8x	3.0x	2.9x	16.4x	22.5x	19.8x
Packaging peers:									
Westrock	10.9x	NA	NA	1.3x	NA	NA	35.1x	NA	NA
MacFarlane Group	7.9x	0.1x	0.1x	0.3x	0.0x	0.0x	12.0x	10.1x	9.1x
Gerresheimer	9.4x	10.0x	9.5x	1.4x	1.5x	1.5x	23.9x	16.9x	15.8x
West Pharmaceutical Services	17.1x	16.5x	14.3x	2.8x	3.5x	3.3x	35.6x	32.8x	27.8x
Convertidora Industrial	9.2x	7.4x	7.3x	0.4x	0.4x	0.3x	25.9x	NA	NA
PSB Industries	6.0x	6.1x	5.6x	0.6x	0.4x	0.4x	10.4x	9.7x	8.5x
Astrapak Ltd	9.9x	NA	NA	0.4x	NA	NA	73.1x	8.1x	5.8x
Bilcare Ltd	7.5x	NA	NA	0.0x	NA	NA	1.7x	NA	NA
Median	9.4x	7.4x	7.8x	0.8x	0.9x	0.9x	22.8x	15.9x	13.1x
High	17.1x	16.5x	14.3x	2.8x	3.5x	3.3x	73.1x	35.1x	27.8x
Low	6.0x	0.1x	0.1x	0.0x	0.0x	0.0x	1.7x	-3.1x	-1.1x
Premium (disc) to peers	46%	(8%)	(25%)	(37%)	(45%)	(47%)	17%	1004%	59%

Source: Bloomberg (as on 16 October 2016)

Exhibit 2: CPH – Comparison with weighted average of division peers

	EV/EBITDA			P/S			P/E		
	3 year average	CY2016E	CY2017E	3 year average	CY2016E	CY2017E	3 year average	CY2016E	CY2017E
Weighted peer multiples	9.3x	7.4x	7.6x	0.8x	0.8x	0.8x	22.4x	13.7x	11.3x
CPH	13.7x	6.8x	5.8x	0.5x	0.5x	0.5x	26.8x	175.3x	20.7x
Premium (disc) to peers	47%	(9%)	(24%)	(39%)	(37%)	(40%)	19%	1178%	84%

Source: Bloomberg (as on 16 October 2016)

DETAILED FINANCIAL STATEMENTS

Income Statement

CHF mn (except per share)	FY11	FY12	FY13	FY14	FY15	FY16E	FY17E
Chemistry sales	101	68	59	60	63	75	88
Paper sales	315	314	306	314	248	261	271
Packaging sales	106	106	116	118	110	122	134
Net Sales	521	489	481	492	420	458	493
Cost of Sales	(338)	(325)	(323)	(313)	(285)	(289)	(307)
Gross profit	182	163	158	180	135	169	186
Personnel cost	(93)	(85)	(86)	(88)	(86)	(89)	(94)
Outsourced maintenance/repairs	(20)	(19)	(19)	(18)	(16)	(14)	(15)
Other operating expense	(23)	(21)	(22)	(23)	(21)	(20)	(23)
Total operating costs	(136)	(125)	(127)	(129)	(123)	(123)	(132)
EBITDA	47	38	31	51	12	46	54
Depreciation on tangible fixed assets	(65)	(59)	(57)	(34)	(34)	(33)	(33)
Depreciation on intangible assets	(2)	(2)	(1)	(1)	(0)	(1)	(2)
Operating profit (EBIT) before impairment	(20)	(22)	(27)	16	(22)	12	18
Impairment	0	0	(251)	0	0	0	0
Operating profit (EBIT)	(20)	(22)	(278)	16	(22)	12	18
Finance costs	(13)	(7)	(5)	(7)	(13)	(6)	(6)
Finance income	1	1	1	2	1	1	1
Total financial income (expenses)	(12)	(6)	(4)	(6)	(12)	(5)	(6)
Profit before taxes (before exceptional items)	(32)	(28)	(281)	10	(34)	7	13
Non-operating items	12	38	2	1	2	(3)	0
Income taxes	2	(2)	8	(1)	(1)	(2)	(1)
Profit attributable to the parent	(18)	8	(271)	11	(33)	1	12
Basic EPS	(3.0)	1.3	(45.2)	1.8	(5.5)	0.2	1.9
Diluted EPS	(3.0)	1.3	(45.2)	1.8	(5.5)	0.2	1.9
DPS	0.7	0.7	0.7	0.7	0.6	0.0	0.8

Source: Research Dynamics, Company data

Balance Sheet

CHF mn	FY11	FY12	FY13	FY14	FY15	FY16E	FY17E
Assets							
Non-current assets							
PPE	769.2	719.7	433.7	419.1	404.3	417.6	405.0
Intangible assets	2.9	1.5	1.2	1.3	2.4	6.4	7.5
Long-term financial assets	0.0	10.0	10.0	10.0	10.0	10.0	10.0
Long-term financial receivables	2.5	0.0	0.0	2.8	0.0	0.0	0.0
Other non-current assets	23.9	21.2	22.4	22.7	20.2	20.2	20.2
Total Non Current Assets	798.5	752.4	467.3	456.0	436.9	454.2	442.8
Current assets							
Inventories	57.3	58.8	56.9	63.4	54.5	54.6	58.4
Trade accounts receivable	75.6	74.0	70.8	79.5	66.4	69.0	74.3
Other receivables	13.2	10.7	7.3	7.7	8.0	8.0	8.0
Prepaid expenses and accrued income	3.9	3.0	5.3	6.6			
Short-term financial receivables	0.9	0.2	0.0	0.1	4.9	4.9	4.9
Liquid funds and Securities	42.6	73.3	74.2	75.1	0.0	0.0	0.0
Total assets	992.1	972.4	681.8	688.4	624.0	646.5	661.6
Shareholders' Equity and Liabilities							
Share capital	30.0	30.0	30.0	30.0	30.0	30.0	30.0
Capital reserves	24.0	20.1	16.2	12.3	8.4	4.8	4.8
Profit reserves	670.3	651.6	659.5	389.2	397.4	364.3	365.7
Net result for the year	(18.0)	8.1	(271.5)	10.5	(33.1)	1.4	11.6
Non-current liabilities							
Long-term financial liabilities	169.3	144.0	117.9	128.0	126.5	146.6	130.0
Pension scheme liabilities	0.6	0.5	0.7	0.6	1.0	1.0	1.0
Other long-term liabilities	0.0	0.0	2.5	2.4	2.3	2.3	2.3
Long-term provisions	32.0	31.3	21.3	20.8	20.0	20.0	20.0
Current liabilities							
Trade accounts payable	40.0	52.9	59.4	53.8	46.7	51.4	54.9
Other payables	6.9	2.6	4.4	3.9	2.6	2.6	2.6
Accrued liabilities and deferred income	12.7	15.8	11.0	9.1			
Short-term financial liabilities					13.6	13.6	13.6
Short-term provisions	11.3	9.8	23.0	22.6	6.8	6.9	23.5
Short-term provisions	12.9	5.7	7.2	5.1	1.5	1.5	1.5
Total liabilities	285.8	262.6	247.5	246.4	221.2	246.0	249.5
Total equity and liab.	992.1	972.4	681.8	688.4	624.0	646.5	661.6

Source: Research Dynamics, Company data

Cash Flow Statement

CHF mn	FY11	FY12	FY13	FY14	FY15E	FY16E	FY17E
Net profit for the period	(18.0)	8.1	(271.5)	10.5	(33.1)	1.4	11.6
Non-cash adjustments:	47.9	20.8	298.8	30.3	35.3	33.9	35.5
Change in current assets and liabilities:							
(Increase)/ decrease in inventories	(2.7)	(1.7)	(2.6)	(5.5)	8.4	(0.1)	(3.7)
Decrease in trade accounts receivable	(20.2)	1.3	3.4	(11.2)	8.1	(2.6)	(5.2)
Increase/ (decrease) in trade accounts payable	(52.0)	13.0	6.4	(5.8)	(6.8)	4.7	3.5
Other changes in working capital	27.5	0.8	(3.0)	1.5	6.5	-	-
Cash flows from operating activities	(17.5)	42.3	31.4	19.8	23.3	37.3	41.6
Investments in tangible fixed assets	(24.4)	(10.9)	(18.2)	(19.2)	(21.9)	(46.4)	(20.9)
Disposals of tangible fixed assets	39.9	30.1	0.9	0.4	1.6	-	-
Investments in intangible assets	(1.4)	(0.3)	(0.5)	(0.6)	(1.6)	(4.8)	(3.2)
Sale of subsidiary/ Divestiture of interests	33.1	-	-	-	-	-	-
Repayment of long-term financial receivables	0.1	2.5	0.0	-	-	-	-
Cash flow generated (used) in investment act.	47.4	21.4	(17.8)	(19.4)	(22.0)	(51.2)	(24.1)
Increase/ (Decrease) in short-term financial liabilities and receivables	3.7	(1.5)	(2.0)	(0.4)	(15.3)	0.1	16.6
Increase/ (Decrease) in long-term financial liabilities	(56.2)	(25.1)	(10.8)	9.8	(1.1)	20.0	(16.6)
Increase in other long-term liabilities	(0.0)	0.0	2.5	(0.2)	(0.1)	-	-
Minority interests and changes resulting from minorities	-	-	-	-	-	-	-
Dividends to shareholders	-	(3.9)	(3.9)	(3.9)	(3.9)	(3.6)	-
Cash flow generated (used) in financing act.	(52.6)	(30.6)	(14.2)	5.3	(20.4)	16.5	(0.0)
Exchange (losses)/gains	(0.1)	0.1	(0.2)	0.2	2.3	-	-
Net change in cash	(22.8)	33.2	(0.7)	6.0	(16.7)	2.6	17.5
Opening cash balance	28.4	5.6	38.8	38.1	69.9	53.1	55.7
Closing cash balance	5.6	38.8	38.1	44.0	53.1	55.7	73.3

Source: Research Dynamics, Company data

Key Ratios

	FY11	FY12	FY13	FY14	FY15	FY16E	FY17E
Growth Ratios							
Sales Growth	25%	(6%)	(2%)	2%	(15%)	9%	8%
Chemistry division	3%	(33%)	(13%)	2%	4%	20%	17%
Paper division	44%	(0%)	(3%)	3%	(21%)	5%	4%
Packaging division	4%	1%	9%	1%	(7%)	11%	10%
Operating Profit Growth	NM	NM	NM	NM	NM	NM	52%
Net Income Growth	NM	NM	NM	NM	NM	NM	744%
Profitability Ratios (%)							
Operating margin (before impairment) (%)	(4%)	(5%)	(6%)	3%	(5%)	3%	4%
Chemistry division	1%	(0%)	(9%)	(4%)	(3%)	2%	5%
Paper division	(8%)	(8%)	(10%)	4%	(11%)	(0%)	1%
Packaging division	4%	5%	6%	4%	5%	10%	7%
EBITDA Margin %	9%	8%	6%	10%	3%	10%	11%
Net Margin (%)	(3%)	2%	(56%)	2%	(8%)	0%	2%
Return Ratios							
Profit Margin	(3%)	2%	(56%)	2%	(8%)	0%	2%
Asset Turnover	0.5x	0.5x	0.6x	0.7x	0.6x	0.7x	0.8x
Financial Leverage	1.5x	1.4x	1.4x	1.6x	1.6x	1.6x	1.6x
Dupont ROE (%)	(3%)	1%	(47%)	2%	(8%)	0%	3%
ROCE (%)	(2%)	(3%)	(5%)	3%	(4%)	2%	3%
ROA (%)	(2%)	1%	(33%)	2%	(5%)	0%	2%
Leverage Ratios							
Debt - Equity Ratio	0.3x	0.2x	0.3x	0.3x	0.3x	0.4x	0.4x
Net Debt - Equity Ratio	0.2x	0.1x	0.2x	0.2x	0.2x	0.2x	0.2x
Interest Coverage	(2.0x)	(3.2x)	(6.0x)	5.2x	(5.5x)	1.9x	2.8x
Liquidity Ratios							
Current Ratio	2.3x	2.5x	2.0x	2.5x	2.6x	2.5x	2.3x
Quick Ratio	1.6x	1.9x	1.5x	1.8x	1.9x	1.8x	1.7x
Valuation Ratios							
EV/EBITDA	9.4x	12.3x	13.7x	6.2x	25.8x	6.2x	5.3x
P/E	NM	48.4x	NM	22.9x	NM	156.1x	18.5x
P/BV	0.4x	0.5x	0.8x	0.5x	0.6x	0.5x	0.5x

Source: Research Dynamics, Bloomberg, Company data

DISCLAIMER

CPH Chemie + Papier Holding AG ("CPH") is a client of Research Dynamics. The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. Research Dynamics is a division of Dynamics Group AG. Dynamics Group is an independent consultancy firm focused on strategic advisory, communication management and research and analysis. This report (henceforth known as "document") has been drafted by the authors concerned as a non-binding opinion on the market situation and on the instruments of investment in question and compiled by Dynamics Group in order to provide background information about the companies. It is intended exclusively for the purpose of information.

Dynamics Group has not individually verified the information and data on which this document is based. All information and data in this document originate from generally available sources which the author concerned or Dynamics Group viewed as reliable at the time of drafting this document. However, no liability can be assumed for their correctness, accuracy, completeness and appropriateness – neither expressly nor tacitly. The contents of this document do not represent an assurance or guarantee by the authors concerned or Dynamics Group. Forward-looking information or statements in this document contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations

Dynamics Group shall not be liable for any consequential damage to properties – on whatever legal grounds it may be. Liability of Dynamics Group on account of premeditation or gross negligence shall remain unaffected by this.

Dynamics Group has no permission to provide assurances or assume guarantees on behalf of the companies or a third party mentioned in this document. Neither the companies mentioned in this document nor any other individual assumes liability for any loss, damage or detriment that may result from the use of this document, especially when taking decisions on investments, or from other reasons. Dynamics Group cannot be held responsible for detrimental consequences that occur or may occur due to the use or its omission based on the views and inferences contained in this document. Past performance trends of value, price or rates do not provide any indications to the future trends for an investment. Dynamics Group does not provide any guarantees for the suggested yield or the achievement of referred targets.

This document does neither represent an offer of purchase, holding or sale of any securities, money market instruments or of derivatives, nor does it contain the basis for a contract or a commitment of any kind. Every investment, for example, in debentures, shares and options, is associated with enormous risks. A decision on investment with regard to any security may not be based on this document. This document is neither an advice on investment, nor a recommendation or invitation for purchasing, holding or selling any securities, money market instruments or derivatives.

Dynamics Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this document. However, the respective directors, employees and contractors of Dynamics Group may hold positions in the described securities and/or options, futures and other derivatives that are based on these securities.

This document has been provided to you for information only. It may not be reproduced or distributed to others or published in any other form partially or fully.

The distribution of this document and the information contained therein may be restricted in other jurisdictions by law and persons who may come into possession of this document must be aware of possible restrictions and adhere to the same. Failure to comply with such restrictions may constitute an infringement of the laws in USA or Canada governing the securities or of the laws of any other jurisdiction.

This study is protected by the copyright laws. It may be used only for the purpose as defined in this disclaimer. Portions of the study, if quoted, must be acknowledged by indicating the source. Any use other than this shall require prior written permission by Dynamics Group. Reproduction, circulation, publication and provision of online access to the document shall be regarded as its use and the same shall require permission. Circulation of this document, especially in a foreign country, may be permitted only under the provisions of the disclaimer and the applicable regulations. Unauthorized use of the study or omission of details of the source or the acknowledgement of copyright may lead to initiation of a civil suit for damages and be liable for prosecution.

If any part or individual formulations of this disclaimer are found to be unsustainable or become unsustainable at a future date, the rest of the contents and their validity shall not be affected by it.

Dynamics Group AG

Utoquai 43
CH-8008 Zürich
Tel. +41 43 268 32 32
Fax +41 43 268 32 39

Zeughausgasse 22
CH-3011 Bern
Tel. +41 31 312 28 41
Fax +41 31 312 28 49

21, rue des Caroubiers
CH-1227 Carouge/GE
Tel. +41 22 308 62 20
Fax +41 22 308 62 36

contact@dynamicsgroup.ch

www.dynamicsgroup.ch